Available Technology

Use of Vitronectin as a Biomarker for the Detection of Dengue Hemorrhagic Fever

Dengue hemorrhagic fever (DHF) is a severe, potentially deadly infection spread by mosquitos. CDC scientists have identified vitronectin as an important biomarker of DHF. They have shown vitronectin is significantly reduced in DHF and severe dengue infections when compared to dengue non-hemorrhagic fever patients. Presently, DHF is established by assessing antibody concentrations and other rule-of-thumb criteria, but often these assays can be difficult to interpret and lead to false conclusions. Establishing vitronectin levels provides a specific, novel biomarker for DHF, leading to increased accuracy in clinical diagnoses and improved patient outcomes.
Abstract: 
Dengue hemorrhagic fever (DHF) is a severe, potentially deadly infection spread by mosquitos. CDC scientists have identified vitronectin as an important biomarker of DHF. They have shown vitronectin is significantly reduced in DHF and severe dengue infections when compared to dengue non-hemorrhagic fever patients. Presently, DHF is established by assessing antibody concentrations and other rule-of-thumb criteria, but often these assays can be difficult to interpret and lead to false conclusions. Establishing vitronectin levels provides a specific, novel biomarker for DHF, leading to increased accuracy in clinical diagnoses and improved patient outcomes.
Benefits: 
While there are commercially-available ELISAs to detect vitronectin, these products have not been used for dengue diagnosis -Vitronectin assessment assays provide a novel, specific biomarker for the DHF disease state -Easily developed for serologic diagnostic assays
applications: 
Inventors: 
Elizabeth Hunsperger
Patent Number: 
61/443,554
Internal Laboratory Ref #: 
E-147-2013/0
Share to Facebook Share to Twitter Share to Google Plus Share to Linkedin